LIXT (Lixte Biotechnology Holdings, Inc. Common Stock) Stock Analysis - Analyst Ratings

Lixte Biotechnology Holdings, Inc. Common Stock (LIXT) is a publicly traded Healthcare sector company. As of May 21, 2026, LIXT trades at $5.53 with a market cap of $54.60M and a P/E ratio of 0.00. LIXT moved +1.90% today. Year to date, LIXT is +48.15%; over the trailing twelve months it is +327.48%. Its 52-week range spans $0.64 to $6.26. Rallies surfaces LIXT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate LIXT?

The average price target is $0.00.

LIXT Key Metrics

Key financial metrics for LIXT
MetricValue
Price$5.53
Market Cap$54.60M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$6.26
52-Week Low$0.64
Volume101.55K
Avg Volume0
Revenue (TTM)$0
Net Income$-6.01M
Gross Margin0.00%

LIXT Analyst Consensus

LIXT analyst coverage data. Average price target: $0.00.

Latest LIXT News

Recent LIXT Insider Trades

  • Bernards Rene bought 5.53K (~$13.87K) on Oct 3, 2023.
  • van der Baan Bastiaan Jeroen bought 10.00K (~$28.00K) on Oct 3, 2023.
  • Bernards Rene bought 5.53K (~$13.87K) on Oct 3, 2023.

Common questions about LIXT

What do analysts rate LIXT?
The average price target is $0.00.
Does Rallies show LIXT price targets?
Yes. Rallies tracks LIXT analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is LIXT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LIXT. It does not provide personalized investment advice.
LIXT

LIXT